Homology Medicines Announces Promotion of Julie Jordan, M.D., to Chief Medical Officer

BEDFORD, Mass., March 09, 2023 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that Julie Jordan, M.D., has been promoted to Chief Medical Officer. Previously, Dr. Jordan held the role of Senior Vice President, Head of Clinical Development and Operations, at Homology, and she has been instrumental in advancing Homology’s gene editing and gene therapy clinical programs. Under her leadership, Homology is conducting the pheEDIT trial for phenylketonuria (PKU) evaluating gene editing candidate HMI-103 designed to maximize PAH enzyme through both genome integration and episomal expression, and the juMPStart trial for Hunter syndrome (MPS II) evaluating systemic gene therapy candidate HMI-203 designed to address peripheral and central nervous system components of the disease. Initial clinical data from pheEDIT is expected mid-year and juMPStart initial data is anticipated in the second half of 2023.

Read more at globenewswire.com